Disease · MONDO_0015924
Comparisons in its trials101
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 101
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tyvaso vs Control: serious adverse events | 96 of 666 | 94 of 667 | 1,333 | NCT01266265 | Trial comparisons |
| Selexipag vs Placebo: serious adverse events | 252 of 575 | 272 of 577 | 1,152 | NCT01106014 | Trial comparisons |
| UT-15C vs Placebo: deaths from any cause | 17 of 346 | 18 of 344 | 690 | NCT01560624 | Trial comparisons |
| UT-15C vs Placebo: serious adverse events | 116 of 346 | 110 of 344 | 690 | NCT01560624 | Trial comparisons |
| Active vs Placebo Arm: Clinical Worsening Assessment | 8 of 174 | 12 of 176 | 350 | NCT00325442 | Trial comparisons |
| Active vs Placebo Arm: serious adverse events | 32 of 174 | 33 of 176 | 350 | NCT00325442 | Trial comparisons |
| Bosentan vs Placebo: serious adverse events | 73 of 159 | 102 of 174 | 333 | NCT00303459 | Trial comparisons |
| Sotatercept Plus Background PAH Therapy (DBPC Period) vs Placebo Plus Background PAH Therapy (DBPC Period): Number of Participants Who Discontinued Study Treatment Due to an AE | 3 of 163 | 10 of 160 | 323 | NCT04576988 | Trial comparisons |
| Sotatercept Plus Background PAH Therapy (DBPC Period) vs Placebo Plus Background PAH Therapy (DBPC Period): Number of Participants Who Experienced an Adverse Event (AE) | 138 of 163 | 140 of 160 | 323 | NCT04576988 | Trial comparisons |
| UT-15C SR vs Placebo: serious adverse events | 23 of 157 | 23 of 153 | 310 | NCT00887978 | Trial comparisons |
| Esuberaprost vs Placebo: deaths from any cause | 26 of 137 | 22 of 136 | 273 | NCT01908699 | Trial comparisons |
| Esuberaprost vs Placebo: serious adverse events | 75 of 137 | 78 of 136 | 273 | NCT01908699 | Trial comparisons |
| Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo): deaths from any cause | 4 of 119 | 12 of 127 | 246 | NCT02558231 | Trial comparisons |
| Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) vs Double Oral Therapy (Macitentan, Tadalafil, and Placebo): serious adverse events | 58 of 119 | 48 of 127 | 246 | NCT02558231 | Trial comparisons |
| LIQ861 Add-On vs Tyvaso Transition: deaths from any cause | 0 of 121 | 0 of 121 | 242 | NCT03399604 | Trial comparisons |
| LIQ861 Add-On vs Tyvaso Transition: serious adverse events | 15 of 121 | 6 of 121 | 242 | NCT03399604 | Trial comparisons |
| Inhaled Treprostinil vs Placebo: serious adverse events | 9 of 115 | 13 of 120 | 235 | NCT00147199 | Trial comparisons |
| UT-15C (Oral Treprostinil) vs Placebo: Clinical Worsening Assessment | 15 of 151 | 8 of 77 | 228 | NCT00325403 | Trial comparisons |
| UT-15C (Oral Treprostinil) vs Placebo: deaths from any cause | 9 of 151 | 6 of 77 | 228 | NCT00325403 | Trial comparisons |
| UT-15C (Oral Treprostinil) vs Placebo: serious adverse events | 27 of 151 | 15 of 77 | 228 | NCT00325403 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015924/comparisons